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Background: Human apolipoprotein E (apoE) exists in three major isoforms: apoE2, apoE3 and apoE4. In the brain,
apoE is produced mostly by astrocytes and transports cholesterol to neurons via apoE receptors. Among the gene
alleles encoding the three isoforms, the APOE4 allele is the strongest genetic risk factor for late-onset Alzheimer’s
disease (AD), whereas APOE2 is protective. ApoE4 confers a gain of toxic function, a loss of neuroprotective function or
a combination of both in AD pathogenesis. Given that therapeutic impacts of modulating apoE expression may be
isoform-dependent, we sought to investigate the relationship between overexpressing apoE isoform and apoE-related
functions in apoE-targeted replacement (TR) mice. Specifically, apoE isoform expression driven by the astrocyte-specific
glial fibrillary acidic protein (GFAP) promoter was built into an adeno-associated virus serotype 8 (AAV8) vector and
injected into the ventricles of postnatal day 2 (P2) apoE3-TR or apoE4-TR mice. Upon confirmation of apoE isoform
expression, effects on apoE lipidation and the levels of amyloid-β (Aβ) in the brain were assessed.
Results: AAV8-GFAP-apoE isoforms were specifically expressed in astrocytes throughout all brain regions, which led to
overall increased apoE levels in the brain. Viral mediated overexpression of apoE4 in the apoE4-TR background
increased poorly-lipidated apoE lipoprotein particles and decreased apoE-associated cholesterol in apoE4-TR mice.
Conversely, apoE2 overexpression in apoE4-TR mice enhanced apoE lipidation and associated cholesterol. Furthermore,
overexpression of apoE4 elevated the levels of endogenous Aβ, whereas apoE2 overexpression trended to lower
endogenous Aβ.
Conclusions: Overexpression of apoE isoforms induces differential effects in the apoE4-TR background: apoE4
decreases apoE lipidation and enhances Aβ accumulation, whereas apoE2 has the opposite effects. Our findings
suggest that increasing apoE2 in APOE4 carriers is a beneficial strategy to treat AD, whereas increasing apoE4 in APOE4
carriers is likely harmful. We have also established novel methods to express apoE isoforms in mouse brain to study
apoE-related pathways in AD and related dementia.
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Alzheimer’s disease (AD) is the leading cause of dementia in
the elderly, which accounts for 60 to 80 percent of dementia
cases [1]. Brain extracellular amyloid plaques and intracellu-
lar neurofibrillary tangles are the two pathological hallmarks
of AD. Apolipoprotein E (apoE) is a major apolipoprotein
and a cholesterol carrier in the brain [2]. The human APOE
gene exists as three major polymorphic alleles: ε2, ε3 and ε4.
Ample evidence indicates that the ε4 allele of the APOE
gene is the strongest genetic risk factor for late-onset AD
(LOAD), whereas the ε2 allele is protective [2-6].
While the primary function of apoE is to deliver choles-
terol and other essential lipids to neurons through binding
to cell surface apoE receptors, apoE also regulates brain me-
tabolism of amyloid-β (Aβ) [7], accumulation of which leads
to deposition of amyloid and is considered the initiating
event in the pathogenesis of AD [8-10]. Previous studies
have shown that brain Aβ levels and amyloid plaque loads
are apoE isoform-dependent (E4 > E3 > E2) both in humans
and in AD transgenic mouse models [11-13]. Several reports
showed that the APOE genotype strongly affects apoE levels
(E4 < E3 < E2) in human cerebrospinal fluid (CSF), brain
parenchyma, and in apoE targeted-replacement (apoE-TR)
mice [14-16]. Analysis on the levels of apoE and Aβ in dif-
ferent brain regions of non-demented individuals found that
apoE levels negatively correlate with Aβ levels both in
APOE4 carriers and non-carriers [17]. ApoE protein levels
in human CSF have also been shown to positively associate
with CSF Aβ42 levels [14]. In addition, liver X receptors
(LXRs) or the retinoid X receptor (RXR) agonists facilitate
Aβ clearance and reverse the memory deficits in amyloid
model mice by increasing apoE levels and its lipidation
[18-20]. These results suggest that apoE levels and lipida-
tion status likely contribute to Aβ clearance; thus, new
therapeutic approaches aimed at increasing apoE expres-
sion are actively being pursued. However, to better design
mechanism-based therapy, it is critical to understand how
increasing apoE expression, in particular apoE4 in APOE4
carriers, impacts apoE lipidation and Aβ metabolism.
Given that apoE is produced predominantly by astrocytes
in the brain [21], we investigated the impact of overexpress-
ing different human apoE isoforms in astrocytes in apoE-TR
mice, in which the coding region of the mouse endogenous
Apoe gene was replaced with one of the three human APOE
alleles without changing the regulatory elements required
for modulation of gene expression [22-24]. Thus, apoE-TR
mice express human apoE isoforms at the physiological
levels and respond to regulatory pathways in a physiological
setting [22-25], providing an excellent in vivo system to
explore the normal function of each APOE allele and apoE-
associated diseases. Here, we used a gene delivery approach
by which adeno-associated viral serotype 8 (AAV8) vectors
expressing various human APOE alleles under the control
of astrocyte-specific glial fibrillary acidic protein (GFAP)promoter were bilaterally injected into the cerebral lateral
ventricles of neonatal apoE3-TR or apoE4-TR mice. We
demonstrated that apoE isoforms are specifically expressed
in astrocytes in the brain three months after injection.
Importantly, we found that increasing apoE4 levels in
apoE4-TR mice led to decreased apoE lipidation, lower
apoE-associated cholesterol, and increased endogenous Aβ.
Conversely, increasing apoE2 expression in apoE4-TR mice
had the opposite, beneficial effects. Our findings for the first
time reveal the consequential effects of overexpressing apoE
isoforms in specific isoform background and should help to
provide guidance for the designs of apoE-based targeted
therapy to treat AD.
Results
Neonatal intracerebroventricular injection of
AAV8-GFAP-apoE viruses results in sustained apoE
isoform expression in astrocytes in mouse brain
Intracerebroventricular injection of neonatal mice using
AAV-based vectors is a relatively easy, fast and efficient way
to modulate gene expression in the brain [26,27]. Previous
studies have shown that when AAV8 viruses are injected
intracranially after P0 of neonatal mice, viral mediated gene
expression is detected primarily in astrocytes [27,28]. To
specifically express apoE isoforms in astrocytes in mouse
brain, we injected AAV8-GFAP viruses carrying cDNAs en-
coding GFP or one of three apoE isoforms into the cerebral
ventricles of P2 neonatal apoE3-TR and apoE4-TR mice. An
HA tag was included in apoE constructs to facilitate protein
detection. Three months after virus injection, expression of
GFP was evaluated in mouse brain. We found that intracra-
nial delivery of AAV8-GFAP-GFP to neonatal mice resulted
in an extensive transduction and GFP expression through-
out the brain, including the cortex and hippocampus
(Figure 1A). To evaluate cell-type specificity of AAV8-
GFAP-mediated expression, we evaluated co-expression of
GFP or apoE isoforms with cell-type specific markers for as-
trocytes, microglia, and neurons by immunofluorescence
staining. We found that both GFP and apoE isoforms, de-
tected with an HA antibody, were co-localized with GFAP-
positive astrocytes, but not with Iba1-positive microglia or
NeuN-positive neurons (Figure 1B-E). These results confirm
that neonatal injection of AAV8-GFAP-apoE leads to sus-
tained expression of apoE isoforms in astrocytes.
AAV-mediated expression of apoE2 is significantly higher
than those of apoE3 and apoE4
We next assessed the mRNA and protein levels of apoE in
the cerebral cortex of apoE3-TR and apoE4-TR mice three
months after injection with AAV8-GFAP-apoE isoforms or
GFP control. Intracerebroventricular injection of AAV8-
GFAP-apoE isoforms significantly increased apoE levels in
the brains of apoE-TR mice compared with mice injected
with GFP control viruses, as detected by real-time PCR
Figure 1 Specific expression of AAV8-GFAP-GFP and AAV8-GFAP-apoE isoforms in astrocytes in vivo. Newborn postnatal day 2 (P2) apoE3-TR
mice were injected intracerebroventricularly with viruses carrying AAV8-GFAP-GFP or AAV8-GFAP-apoE isoforms. Expression of GFP or apoE isoforms
was evaluated 3 months after viral injection. (A) GFP expression was detected by green fluorescence and the images from different brain regions are
shown. (B-E) Mouse brain sections transduced with AAV8-GFAP-GFP (B), AAV8-GFAP-apoE2 (C), AAV8-GFAP-apoE3 (D) or AAV8-GFAP-apoE4 (E) were
co-immunostained with HA antibody for apoE expression and antibodies for cell type-specific markers (GFAP: astrocyte; Iba1: microglia; NeuN: neuron).
Note that apoE (HA immunoreactivity) is specifically expressed in GFAP-positive astrocytes.
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While the apoE mRNA levels were not significantly different
among apoE isoforms (Figure 2A and C), we found that the
apoE protein levels are significantly higher in apoE-TR mice
transduced with AAV8-GFAP-apoE2 viruses compared
with those transduced with GFP, apoE3 or apoE4 viruses
(Figure 2B and D). These results are consistent with a previ-
ous study [15] indicating that apoE2 is likely a more stable
isoform compared with apoE3 and apoE4.
Increasing apoE4 expression leads to decreased apoE
lipidation in apoE4-TR mice
ApoE lipidation is critical for its function in maintaining
synapses [2,3,20]. Studies in humans [29] and in apoE-TR mice [30,31] suggest that apoE4 is significantly less
lipidated than apoE2 and apoE3. To investigate the lipi-
dation status of apoE in apoE-TR mice transduced with
AAV8-GFAP-apoE isoforms, apoE-associated lipoprotein
particles in the cortical brain lysates were evaluated by
non-denaturing gel electrophoresis, followed by Western
blotting (Figure 3). ApoE-immunoreactivity was detected
in the molecular sizes between 242 and 1048 kDa. To
quantify the distribution of apoE/lipoprotein particles,
we defined particle sizes as large, medium and small
(Figure 3A). Importantly, we found that the amounts of
large apoE/lipoprotein particles were reduced and the
small particles were increased in apoE4-TR mice trans-
duced with AAV8-GFAP-apoE4 viruses compared with
Figure 2 Increased apoE expression in apoE-TR mice following AAV viral mediated expression of apoE isoforms in neonatal mice. Neonatal
P2 apoE3-TR or apoE4-TR mice were injected intracerebroventricularly with viruses carrying AAV8-GFAP-GFP or AAV8-GFAP-apoE isoforms, and mouse
brains were harvested 3 months after viral injection. (A and B) Levels of apoE mRNA (A) and protein (B) in the cortices of apoE3-TR mice transduced
with viruses encoding GFP or apoE isoforms were analyzed by real-time PCR or apoE-specific ELISA, respectively. (C and D) Same as in A and B, except
apoE4-TR mice were used. Data are expressed as mean ± SEM (n = 7-8/group). *,p < 0.05; **,p < 0.01; ***,p < 0.001.
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trast, apoE4-TR mice transduced with AAV8-GFAP-
apoE2 viruses exhibited increased amounts of large apoE
particles and decreased amounts of small particles
(Figure 3B). In like manner, transduction of AAV8-
GFAP-apoE2 viruses in apoE3-TR mice increased the
large particles, whereas transduction of AAV8-GFAP-
apoE4 viruses increased the small particles (Additional
file 1: Figure S1). These results indicate that apoE4 is as-
sociated with poorly and apoE2 abundantly lipidated
particles.
To further evaluate apoE lipidation status, we next quan-
tified the amounts of cholesterol associated with apoE iso-
forms in the buffer/TBS-soluble fractions of apoE3-TR and
apoE4-TR mice transduced with different viruses. The
apoE-containing particles were immunoprecipitated with a
biotinylated apoE antibody and the amounts of cholesterol
co-immunoprecipitated with apoE were quantified. Trans-
duction of AAV8-GFAP-apoE isoforms increased the levelsof apoE and apoE-associated cholesterol in both apoE3-TR
mice (Additional file 1: Figure S2A and B) and apoE4-TR
mice compared with those transduced with GFP control
(Figure 4A and B). Interestingly, mice transduced with
apoE2 had the highest apoE and cholesterol levels
(Figure 4A and B; Additional file 1: S2A and B). In addition,
the cholesterol-to-apoE ratio was significantly increased in
apoE4-TR mice transduced with apoE2, while it was de-
creased among apoE4-TR mice transduced with apoE4
(Figure 4C). We did not observe a significant difference in
the ratio of cholesterol-to-apoE in apoE3-TR mice trans-
duced with AAV8-GFAP-apoE isoforms compared with
controls (Additional file 1: Figure S2C). Further, there were
no significant differences in the levels of ATP-binding
cassette transporters A1 (ABCA1) and ATP-binding cas-
sette transporters G1 (ABCG1), two major cholesterol
transporters, in apoE3-TR or apoE4-TR mice transduced
with AAV8-GFAP-apoE isoforms compared with controls
(Additional file 1: Figure S3). These results indicate that
Figure 3 Viral mediated expression of apoE4 in apoE4-TR mice shifts apoE particles to smaller sizes. Neonatal P2 apoE4-TR mice were
injected with AAV viruses and brains were harvested as in Figure 2. (A) ApoE-associated particles in the TBS fractions of cortical brain tissues were
analyzed by native gel electrophoresis. ApoE particle-immunoreactivity was detected at approximately between 242 kDa and 1048 kDa, and
defined as three categories of particle sizes: Large particles (>720 kDa); Medium particles (480–720 kDa) and Small particles (<480 kDa). Cortical
lysates from age-matched Apoe knockout (KO) mice was used as a negative control for apoE immunoreactivity. (B) The percentages of apoE
particles in different size categories were quantified. Data are expressed as mean ± SEM (n = 3-5). *,p < 0.05; **,p < 0.01; ***,p < 0.001.
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creases apoE-associated cholesterol in the brains in an
isoform-dependent manner.
ApoE4 overexpression in the brain of apoE4-TR mice
results in increased Aβ accumulation
Mounting evidence indicates that apoE regulates Aβ metab-
olism, aggregation and deposition in an isoform-dependent
manner [7,32] and that Aβ clearance is slower in apoE4-TR
mice compared with apoE3-TR mice [12]. In addition, many
studies suggest that lipid-poor apoE promotes Aβ aggrega-
tion while fully lipidated apoE favors Aβ clearance
[20,26,27]. In this study, we found that AAV8-mediated
transduction of apoE in astrocytes regulated apoE lipidation
in an isoform-dependent manner. We thus examined the
differential effects of increasing apoE isoforms on Aβmetab-
olism in the brains of apoE3-TR and apoE4-TR mice. Trans-
duction of various apoE isoforms in apoE3-TR mice did notsignificantly impact the levels of endogenous Aβ40 in the
cortex (Figure 5A). However, when apoE isoforms were
overexpressed in the background of apoE4-TR mice,
apoE4 significantly increased the levels of endogenous
Aβ40 whereas apoE2 trending to the opposite (Figure 5B).
We further performed correlation analyses between the
levels of apoE and endogenous Aβ40 in apoE4-TR mice
transduced with different viruses (Figure 6A-D) and found
that the levels of endogenous Aβ40 positively correlated
with those of apoE in apoE4-TR mice transduced with
AAV8-GFAP-apoE4 viruses (Figure 6D). In contrast, there
was a trend of negative correlation between the levels of
Aβ40 and apoE in apoE4-TR mice transduced with AAV8-
GFAP-apoE2 viruses (Figure 6B). There were no signifi-
cant correlations between the levels of endogenous Aβ40
and apoE in apoE3-TR mice transduced with viruses
expressing different apoE isoforms (Additional file 1:
Figures S4A-D). To determine whether transduction of
Figure 4 Viral mediated expression of apoE4 in apoE4-TR mice leads to reduced levels of apoE-associated cholesterol. Neonatal P2
apoE4-TR mice were injected with AAV viruses and brains were harvested as in Figure 2. Mouse cortical brain tissues were lysed in TBS and the
apoE-associated particles were isolated by immunoprecipitation using a biotinylated-apoE specific antibody. Mice injected with GFP viruses
treated with beads only were used as a negative control. (A) The immunoprecipitated apoE under different conditions was detected by Western
blot. (B) ApoE-associated cholesterol was analyzed by Amplex Red Cholesterol Assay. (C) The ratios of cholesterol-to-apoE under each condition
were calculated. Data are expressed as mean ± SEM (n = 3-5/group). *,p < 0.05; **,p < 0.01; ***,p < 0.001.
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precursor protein (APP) in mouse brains, we analyzed the
levels of full-length APP, APP α- and β-C-terminal frag-
ments (α-CTFs and β-CTFs) in apoE3-TR and apoE4-TR
mice. Transduction of AAV8-GFAP-apoE viruses did not
significantly affect the levels of full-length APP, APP α-CTF
or β-CTFs in apoE3-TR or apoE4-TR mice compared with
those transduced with GFP control viruses (Additional
file 1: Figure S5A and B), suggesting that overexpression of
apoE isoforms does not affect APP expression or process-
ing. Together, these results suggest that increasing theFigure 5 Viral mediated expression of apoE4 in apoE4-TR mice leads
apoE4-TR mice were injected with AAV viruses and brains were harvested a
cortices of apoE3-TR mice (A) or apoE4-TR mice (B) transduced with AAV v
Aβ-specific ELISA. Data are expressed as mean ± SEM (n = 7-8/group). N.S., Nexpression level of apoE4 is likely detrimental, while apoE2
is beneficial, in regard to brain Aβ accumulation.
Discussion
The most prevalent genetic risk factor for late-onset AD
is the APOE genotype with an allele-specific risk profile:
APOE4 >APOE3 >APOE2 [33,34]). Despite progress in
the past two decades [2,3], it remains unclear how apoE4
increases, and apoE2 decreases, the risk of AD. The
amyloid hypothesis proposes that an imbalance between
Aβ production and clearance leads to Aβ accumulationto increases of mouse endogenous Aβ. Neonatal P2 apoE3-TR or
s in Figure 2. (A and B) Levels of mouse endogenous Aβ in the
iruses encoding GFP or apoE isoforms were quantified by mouse
ot significant; *,p < 0.05; **,p < 0.01.
Figure 6 Positive correlations between mouse endogenous Aβ and apoE in apoE4-TR mice transduced with AAV8-GFAP-apoE4 viruses.
Three months after intracranial delivery of viruses carrying AAV8-GFAP-GFP or AAV8-GFAP-apoE isoforms, the levels of mouse endogenous Aβ40
and apoE in the cortices of apoE4-TR mice were examined by Aβ40-specific ELISA and apoE-specific ELISA, respectively. (A-D) The correlation
between levels of Aβ40 and apoE in the cortex of apoE4-TR mice transduced with GFP (A), apoE2 (B), apoE3 (C) or apoE4 (D) were analyzed and
plotted. The Pearson correlation coefficient (r) and p values are shown.
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lines of evidence demonstrate that apoE isoforms differen-
tially regulate Aβ metabolism in the brain [35-38], likely
through modulation of Aβ clearance and aggregation
[3,12,32]. These findings suggest that apoE levels, lipida-
tion status and isoform-dependent effects may differently
impact Aβ metabolism, thereby contributing to or pre-
venting AD pathogenesis.
In the current study, we used AAV8 constructs driven
by an astrocyte-specific GFAP promoter to express three
apoE isoforms (AAV8-GFAP-apoE2/3/4) in neonatal
apoE3-TR or apoE4-TR mice through intracranial injec-
tion. Transduction of AAV8-GFAP-apoE led to sustained
expression of apoE isoforms in mouse brain. We found
that transduction of apoE4 in apoE4-TR background sig-
nificantly increased the amounts of small, lipid-poor apoE
particles and the levels of endogenous Aβ. Conversely,
transduction of apoE2 in the apoE4-TR background led to
an increase in the amounts of large, lipid-rich apoE parti-
cles and decreased endogenous Aβ. Our findings indicatethat modulating the levels of apoE isoforms had differen-
tial effects on the lipidation status of apoE and Aβ levels
in apoE4-TR, less so in apoE3-TR mice. Specifically, over-
expression of apoE2 and apoE4 in apoE4 background
leads to opposite effects on the amounts of cholesterol as-
sociated with apoE and Aβ accumulation with apoE4 be-
ing detrimental and apoE2 beneficial. We did not observe
significant changes in APP proteolytic processing products
in mice transduced with different apoE isoforms, indicat-
ing that APP processing to Aβ is not regulated by the ex-
pression levels of apoE isoforms.
A recent study assessed the effects of overexpressing apoE
isoforms in the background of amyloid model mice with en-
dogenous murine apoE background [39]. They found that
overexpression of apoE4 leads to higher levels of Aβ and en-
hanced amyloid deposition, whereas overexpression of
apoE2 had the opposite effects. Our current study uniquely
address how overexpression of apoE isoforms in different
human apoE isoform background impact apoE lipidation
and Aβ accumulation, events that are critical for the
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bined, these studies should provide mechanism-based guid-
ance on regulating apoE expression and lipidation in the
designs of therapeutic approaches to treat AD.
The mechanism underlying the protective effect of
apoE2 against AD remains unclear. Our results show
that apoE protein levels are significantly higher in mice
transduced with apoE2 compared with mice transduced
with GFP controls, apoE3 or apoE4 viruses, despite simi-
lar mRNA levels. Previous studies have shown that
apoE2 may exhibit a more stable conformation [40] and
has lower affinity to the low-density lipoprotein (LDL)
receptor, which may lead to decreased catabolism [15].
Thus, the higher levels of apoE observed in apoE2-
transduced mice may be attributed to its increased sta-
bility and decreased turnover. Previous studies suggest
that formation of protein complexes between apoE and
Aβ may facilitate Aβ clearance [41]. Compared with
apoE2 or apoE3, apoE4/Aβ complexes have been shown
to be less stable, which is likely attributed to the poor
lipidation status of apoE4/lipoprotein particles [7,31,42].
In addition, complex formation between Aβ and apoE
isoforms may affect their binding property to their indi-
vidual or common receptors including the low-density
lipoprotein receptor-related protein 1 (LRP1), thereby
further affects Aβ clearance [32,43]. Thus, it is possible
that overexpression of apoE2 increases and apoE4 de-
creases apoE/Aβ complex formation and therefore, the
clearance of Aβ in the brain.
Emerging evidence indicates that apoE lipidation status
directly affects its role in Aβ clearance [20,44,45]. Our
current study demonstrates that AAV-mediated transduc-
tions of apoE isoforms have different effects on the lipida-
tion status of apoE. Compared with controls, transduction
of apoE4 in apoE4-TR mice increased the proportion of
poorly-lipidated apoE. Several studies suggest that apoE4 is
significantly less lipidated than apoE2 and apoE3 in both hu-
man and APP transgenic mice expressing human apoE iso-
forms [29-31]. ApoE4 more easily self-aggregates, which
may affect its lipidation capacity [46]. Hence, it is possible
that overexpression of apoE4 in apoE4-TR mice results in
apoE4 aggregation, which might impair its lipidation. Con-
sistent with this notion, haploinsufficiency of ABCA1, which
mediates apoE lipidation, impairs Aβ clearance and exacer-
bates amyloid deposition in apoE4-TR mice, but not in
apoE3-TR mice [47]. Though we did not observe an alter-
ation in the levels of ABCA1 and ABCG1, boosting apoE4
in apoE4-TR mice may enhance apoE4 aggregation in paral-
lel with an impairment of its lipidation, which in turn de-
creases Aβ clearance and/or promotes Aβ deposition.
In addition to its effects on Aβ metabolism, apoE me-
diates neuronal delivery of cholesterol, an essential com-
ponent for synaptic plasticity required for learning and
memory formation [2]. Given the ongoing clinical trialaimed at increasing apoE levels and its lipidation [20], it
is imperative to understand the consequences of boost-
ing apoE on cholesterol homeostasis and Aβ metabolism
in the background of different apoE isoforms. Our
current study directly demonstrates the divergent effects
of apoE2 and apoE4 isoforms on Aβ accumulation and
apoE lipidation status, effects that are more pronounced
in apoE4-TR mice.
Conclusions
Here, we report that increasing apoE4 in the brain of
apoE4-TR mice reduces lipid-rich apoE and promotes Aβ
accumulation, while increasing apoE2 in the brain leads to
opposite effects. To the best of our knowledge, this is the
first report demonstrating the impact of boosting different
apoE isoforms in astrocytes on cholesterol and Aβ metab-
olism in the brain of apoE3-TR or apoE4-TR mice. Our
findings suggest that astrocyte expression of apoE2 iso-
forms through AAV-mediated transduction or delivery of
apoE2 mimetic into the brain might have therapeutic
value, while increasing apoE4 in the brain may be harmful,
especially for carriers of the APOE4 allele.
Materials and methods
Animals
Human apoE3-TR or apoE4-TR mice, which express re-
spective human apoE isoform driven by the endogenous
murine ApoE promoter, were obtained from Taconic. All
animal experiments were conducted in compliance with
the protocols of the Institutional Animal Care and Use
Committee at Mayo Clinic.
Viral vector construction and production
The AAV8 vector construction and production were per-
formed by the Hope Center Viral Vectors Core at the
Washington University School of Medicine. ApoE2, 3, or
4 cDNA in pcDNA3.1 was amplified by PCR with the for-
ward primer containing a BamHI site and the reverse pri-
mer containing a SalI site and an influenza hemagglutinin
(HA) tag sequence. The PCR products were digested with
BamHI and SalI and inserted into an AAV8-GFAP-GFP
backbone in which the GFP was replaced with the PCR
products. The resulting AAV8-GFAP-aopE2-HA, AAV8-
GFAP-aopE3-HA, and AAV8-GFAP-aopE4-HA contain
the respective apoE isoforms with a HA tag under the
control of a GFAP promoter. The AAV8 viruses were pro-
duced as previously described [48]. Briefly, the packaging
cell line HEK293 is maintained in Dulbecco’s modified Ea-
gles medium (DMEM), supplemented with 5% fetal bovine
serum (FBS), 100 units/ml penicillin, 100 μg/ml strepto-
mycin in 37°C incubator with 5% CO2. The cells were co-
transfected with pAAV2/8, pHelper, and rAAV transfer
plasmid containing GFP or apoE isoforms using the cal-
cium phosphate precipitation method. The cells were
Hu et al. Molecular Neurodegeneration  (2015) 10:6 Page 9 of 11incubated at 37°C for 3 days before harvesting. Cells were
lysed by three freeze/thaw cycles. The cell lysate were
treated with 50U/ml of Benzonaze followed by iodixanol
gradient centrifugation. The iodixanol gradient fraction is
further purified by HiTrap Q column chromatography
(GE Healthcare) and concentrated with Vivaspin concen-
trator (Bohemia, NY). The virus titer was determined by
dot blot assay.
Intracranial injections in neonatal mice
AAV8 virus intracranial injection in neonatal mice was
performed as previously described with minor modifica-
tions [27,28]. Briefly, postnatal day 2 (P2) mice were
cryoanesthetized on ice for 5 min and injected intracereb-
roventricularly with 2 μl (~1013 viral particles/ml) of vi-
ruses into both hemispheres using a syringe (7642–01,
Hamilton) with a 30 gauge needle (7803–07, Hamilton).
After injections were complete, pups were placed on a
warming pad until they regained normal color and re-
sumed movement. All injected animals were then returned
to their mothers for further recovery.
Preparation of mouse brains
Three months post AAV virus injection, mice were anesthe-
tized using isoflurane, perfused with PBS, and their brains
were rapidly harvested. The right hemibrains were fixed in
4% paraformaldehyde and used for immunofluorescence
analysis, and left hemibrains were dissected and kept frozen
at −80°C until further biochemical analysis.
Immunohistochemistry
The immunohistochemistry for the brain sections was
performed as previously described [27]. Briefly, brains
were fixed overnight at 4°C in fresh 4% paraformalde-
hyde and then transferred to 30% sucrose for cryopro-
tection. Brains were frozen on dry ice and then
sectioned at 45 μm using a freezing-sliding microtome
(LEICA SM2400, Leica). Sections were permeated and
blocked with 3% goat serum containing 0.1% Triton-X
100 in Tris-buffered saline (TBS) buffer (25 mM Tris,
0.15 M NaCl, pH 7.4) for 1 h at room temperature.
Then, the sections were incubated with mouse anti-HA
(1:1000, Covance), rabbit anti-GFAP (1:1000, Millipore),
rabbit anti-NeuN (1:1000, Millipore) or rabbit anti-Iba1
(1:1000, Wako Chemicals) antibodies in blocking solu-
tion at 4°C overnight. The sections were washed with
TBS/0.5% Tween 20 (TBST) and incubated with Alexa
Fluor 488-conjugated goat anti-mouse (1:400; Invitro-
gen) and Alexa Fluor 568-conjugated donkey anti-rabbit
(1:400; Invitrogen) secondary antibodies for 2 h at room
temperature. Images were obtained by confocal micro-
scope (LSM 510 META, Zeiss) and analyzed by ZEN
software.Quantitative real-time PCR
Total RNAs were extracted from frozen cortical tissues
using Trizol (Invitrogen) and Direct-zol RNA MiniPrep
kit (Zymo Research). Reverse transcription was performed
using SuperScript III First-Strand Synthesis System (Invi-
trogen). Real-time qPCR was conducted with Universal
SYBR Green Supermix (Bio-Rad) using an iCycler thermo-
cycler (Bio-Rad). The following primers were used: Hu-
man apoE mRNA forward primer, TGTCTGAGCAGG
TGCAGGAG; and reverse primer, TCCAGTTCCGATTT
GTAGG. Mouse β-actin forward primer, AGTGTGACGT
TGACATCCGTA; and reverse primer, GCCAGAGCAG
TAATCTCCTTC Relative mRNA levels were calculated
by ΔΔCt method with β-actin used as a reference.ELISA for human apoE
Cortical tissues were homogenized with a Polytron
homogenizer in ice cold TBS buffer containing protease
inhibitor and phosphate inhibitor cocktails (Roche). The
homogenates were centrifuged at 100,000 g for 30 min
at 4°C and the supernatants were collected. ApoE levels
were analyzed using an ELISA. Briefly, 96-well plates
were coated overnight with an apoE antibody (AB947,
Millipore) in carbonate buffer at 4°C overnight. The
plates were blocked with 1% Block Ace in PBS, and then
washed with PBS 3 times. Recombinant apoE (Fitzgerald)
along with samples were diluted and added at a volume of
100 μl/well incubated at 4°C overnight. The plates were
washed and incubated with biotin-conjugated goat anti-
apoE antibody (Meridian Life Science) for 2 h at room
temperature. After incubation with Horseradish Peroxid-
ase Avidin D (Vector Laboratories) for 90 min at room
temperature, the plate was developed by adding tetra-
methylbenzidine Super Slow substrate (Sigma). The reac-
tion was stopped and read at 450 nm with a microplate
reader.ELISA for mouse endogenous Aβ
Mouse endogenous Aβ was extracted from cortical tissues
by diethylamine as previously described [49]. The Aβ
levels in age-matched APP knockout mice were used as a
negative control and subtracted as background. For detec-
tion of endogenous mouse Aβ40, 96-well plates were
coated at 4°C overnight with 13.1.1 mAb (anti-Aβ35-40)
[49,50]. The plates were blocked with 1% Block Ace in
PBS, washed with PBS and loaded with samples. Synthetic
rodent Aβ40 (AnaSpec) was used as standards. Following
overnight incubation at 4°C, the plates were washed,
followed by incubation with HRP-conjugated mAb 32.4.1
(rodent Aβ1-16 specific) [49] for detection. The plates
were developed with tetramethylbenzidine Supersensitive
substrate (Sigma). The reaction was stopped and read at
450 nm with a microplate reader.
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Cortical tissues were homogenized with a Polytron
homogenizer in ice cold TBS buffer containing protease
inhibitor and phosphate inhibitor cocktails (Roche).
Proteins were separated by Native PAGE™ Novex 4–16%
Bis-Tris gels (Invitrogen) under native conditions fol-
lowing the manufacturer’s instructions and transferred
to PVDF (Millipore) at 100 V for 1 h using the Trans-
Blot Cell (Bio-Rad). Blots were treated with Ponceau S
Staining Solution (0.1% (w/v) Ponceau S in 5% (v/v)
acetic acid) to visualize the molecular mass markers.
The NativeMark Unstained Protein Standard from Invi-
trogen was used for estimation of particle sizes. After
washing in TBS, blots were processed for Western blot.
The membrane was incubated with goat anti-apoE anti-
body (K74180B, Meridian Life Science) overnight at
4°C, followed by peroxidase-labeled donkey anti-goat
antibody (Santa Cruz). The membrane was developed
with Lumigen ECL Ultra Western Blotting HRP Sub-
strate (Lumigen), and the signals were detected by Fuji
film Luminescent Image Analyzer (LAS4000). An anti-
body that recognizes the C-terminus of APP (18961,
IBL-America) was used for detecting APP and its C-
terminal fragments. Anti-β-actin (Sigma) was used as a
loading control. Western blot bands were quantified by
Image J software.
Immunoprecipitation (IP) of apoE particles and
cholesterol assay
Streptavidin-conjugated agarose beads (Sigma) were
first incubated with biotin-conjugated goat anti-apoE
antibody (K74180B, Meridian Life Science) for 2 h at
room temperature with shaking. The unbound anti-
bodies were removed by washing with TBS three times.
The antibody-bound agarose beads were then mixed
with brain lysates in TBS fractions (500 μg total protein)
at 4°C overnight. The IP solution was centrifuged for
2 min at 1,000 g to collect agarose beads. The beads
were washed with cold TBS three times and re-
suspended with TBS/0.1% Triton X-100. The resulting
suspension was subjected to Western blot analysis in
which equal volumes of samples were loaded. Proteins
were separated by 4-20% Mini-PROTEAN TGX Gel
(Bio-Rad) and transferred to Immobilon-P PVDF (Milli-
pore). The membranes were incubated with apoE anti-
body (K74180B, Meridian Life Science), followed by
IRDye secondary antibody (LI-COR Biosciences). The
results were visualized and quantified by Odyssey
infrared imaging system (LI-COR Biosciences). The
remaining suspension was used for the detection of
apoE particle-associated cholesterol quantified by
Amplex Red cholesterol assay (Invitrogen) according to
the manufacturer’s protocol.Statistical analysis
All data were analyzed by one-way analysis of variance
(ANOVA) with a Tukey’s post-hoc test using GraphPad
Prism 5. Data were presented as average ± SEM. A p value
of < 0.05 was considered statistically significant.
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Additional file 1: Figure S1. Analysis of apoE-associated lipoprotein
particles in apoE3-TR mice transduced with viruses carrying AAV8-GFAP-
apoE isoforms. Figure S2. ApoE-associated cholesterol levels in apoE3-TR
mice transduced with viruses carrying AAV8-GFAP-apoE isoforms. Figure S3.
Overexpression of apoE isoforms does not affect the levels of ABCA1 and
ABCG1 in apoE-TR mice. Figure S4. Correlation analysis between mouse
endogenous Aβ and apoE in apoE3-TR mice transduced with viruses
carrying AAV8-GFAP-apoE isoforms. Figure S5. APP expression and
processing are not altered in apoE-TR mice upon overexpression of apoE
isoforms.
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